Zydus Cadila has received the final approval from the USFDA to market Donepezil Hydrochloride Tablets, in the strength of 23 mg. The drug is indicated for the treatment of dementia of the Alzheimer’s disease.
The drug will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. The group now has more than 140 approvals and has so far filed over 300 AND As since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
